<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984074</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000654169</org_study_id>
    <secondary_id>UPCC-808258</secondary_id>
    <nct_id>NCT00984074</nct_id>
  </id_info>
  <brief_title>MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer</brief_title>
  <official_title>A Pilot Study of Functional Mapping and Brain Perfusion Imaging in Patients Receiving Base of Skull and Brain Radiotherapy: Developing Neurocognitive Functional Organs At Risk for Individualized Conformal Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as specialized types of magnetic resonance imaging
      (MRI), may help in planning radiation therapy that does less damage to normal tissues.

      PURPOSE: This phase I trial is studying using functional MRI to see how well it works in
      planning radiation therapy in patients undergoing radiation therapy to the base of the skull
      and/or brain for nonmetastatic head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the feasibility of applying established MRI techniques to map functional
           anatomic regions at potential risk in irradiated normal brain tissue of patients
           undergoing radiotherapy to the base of the skull and brain for head and neck neoplasms.

        -  To determine changes in cerebral blood flow and blood volume with perfusion MRI
           techniques in irradiated regions of the brain as a function of the radiation dose.

      OUTLINE: Patients undergo MRI perfusion imaging and functional (fMRI) (standard structural
      imaging sequences, diffusion tensor imaging, arterial spin labeled perfusion imaging at rest,
      blood oxygen level dependent, and dynamic susceptibility contrast perfusion weighted MRI) at
      baseline and 3 and 6 months after completion of radiotherapy. Patients may perform tasks for
      fMRI studies, including finger tapping, photic stimulation with a flashing light, solving
      math problems, comparing shapes, giving a speech, or listening to and reciting lists of words
      during fMRI image acquisition. Patients also undergo daily fractionated intensity-modulated
      radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Feasability, as assessed by the proportion of study patients with functional regions identified within the brain as receiving exit irradiation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary parameters of the dose volume histograms to the functional regions identified</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow and blood volume quantitated by relative measures normalized to regions of the brain not receiving any irradiation</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood-oxygen-level-dependent functional magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion tensor imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic contrast-enhanced magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>functional magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy treatment planning/simulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed head and neck cancer that requires radiotherapy to the base
             of the skull

          -  No evidence of metastatic disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Life expectancy â‰¥ 1 year

          -  Not pregnant

          -  Negative pregnancy test

          -  Able to undergo standard CT simulation and radiotherapy treatment planning and
             delivery, including the capacity to comply with standard immobilization devices to the
             head and neck for daily irradiation

          -  Able to undergo standard MRI and deemed capable of complying with the immobilization
             needs and tasks required for functional MRIs

          -  No claustrophobia

          -  No patients with pacemakers, metal fragments in the eye, or certain metallic implants

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Quon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Mehler</last_name>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Abramson Cancer Center of the Univers</last_name>
      <phone>800-474-9892</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stephen Michael Hahn</name_title>
    <organization>Abramson Cancer Center of the University of Pennsylvania</organization>
  </responsible_party>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage I mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage I verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage II adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage II mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage II verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I basal cell carcinoma of the lip</keyword>
  <keyword>stage II basal cell carcinoma of the lip</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland acinic cell tumor</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>salivary gland adenoid cystic carcinoma</keyword>
  <keyword>salivary gland anaplastic carcinoma</keyword>
  <keyword>salivary gland malignant mixed cell type tumor</keyword>
  <keyword>salivary gland poorly differentiated carcinoma</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage I salivary gland cancer</keyword>
  <keyword>stage II salivary gland cancer</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

